Abstract Body

Background: In vitro killing of HIV-infected cells by cytotoxic T lymphocytes (CTL) is a surrogate marker of CTL antiviral efficacy. Tetrameric peptide-MHC complexes (tetramers) enable identification of antigen-specific CD8+ T cells in a mixed population. Due to their rapid internalization by cognate T cells, tetramers are an effective delivery vehicle of any coupled moiety to target specific CTL. Novel tetramers conjugated to saporin (SAP), a potent toxin causing cell death through ribosome-inactivation, have been used in vivo to deplete murine diabetogenic T cells, but no human reports exploiting this technology exist to date. Here, we used toxic tetramers to rapidly eliminate or ‘zap’ human CTL of different specificities in order to compare their anti-HIV potency.

Methods: PBMC were treated with HLA-matched SAP-coupled tetramers (tet-SAP) or a control (HLA-matched tet-PE, HLA-mismatched tet-SAP, free SAP) and cell loss was quantified by flow cytometry. In inhibition assays, CD8+ T cells were expanded, treated with tet-SAP or a control and added as effectors to HLA-matched target cells infected with NL4-3-GFP, used as a marker to measure viral inhibition.

Results: We show that HLA-matched tet-SAP but not HLA-mismatched tet-SAP or free SAP selectively binds to the surface of antigen-specific CD8+ T cells and is then rapidly internalized by the cognate cells alike a conventional tet-PE of the same specificity. We further show that, by as little as 48h post-tet-SAP treatment, up to 97% of tetramer-specific cells are eliminated from the diverse CTL population (Fig 1A). This elimination is highly targeted pertaining exclusively to the desired specificity. Finally, we compare the abilities of zapped, untreated or control-treated CTL to inhibit viral replication, using CD8+ T cells from an HLA-B*27:05+ controller with the dominant B*27:05-Gag-KK10 response. We observe that untreated bulk and control-treated CD8+ T cells effectively inhibit viral replication, but zapped CTL lacking KK10-specific cells lose this suppressive capacity (Fig 1B).

Conclusions: We have optimized a novel method to eliminate CTL of different specificities and thereby measure their individual contribution to viral suppression. This rapid, efficient, cost-saving method, applicable to any HLA type, will enable us to discriminate between the most efficacious and futile CTL responses in HIV infection and answer the long-standing question of the quality of different responses – the holy grail of a therapeutic HIV vaccine research.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V
Figure: (A) Representative FACS plots showing HLA-B*27:05-KK10+ CD8+ T cells in an HIV+ subject (left) and their elimination 48h after KK10-SAP treatment (right). Numbers indicate %liveCD3+CD8+tetramer+ cells. (B) Viral inhibition assay showing loss of the suppressive capacity by KK10-zapped cells.